Bayer: core EPS down 4% in Q1
At almost 13.8 billion euros, the German group's sales fell by 0.6% in organic terms, with decreases of 3% in agrochemicals and 1.8% in consumer health care, but an increase of 3.9% in pharmaceuticals.
Bayer confirms its currency-adjusted guidance for 2024, although a negative currency impact has led it to reduce its target range for EBITDA excluding non-recurring items from €10.4-11 billion to €10.2-10.8 billion.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction